Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOND: CG0070 in BCG-unresponsive NMIBC
NCT01438112Phase 3Terminated
- Sponsor
- CG Oncology, Inc.
- Start
- Mar 2014
- Primary completion
- Jun 2016
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 3 trial of cretostimogene grenadenorepvec in non-muscle-invasive bladder cancer (NMIBC), sponsored by CG Oncology, Inc.. Started Mar 2014; status: terminated.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT01438112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438112.